Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Moores Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Immunity. 2019 Jul 16;51(1):15-26. doi: 10.1016/j.immuni.2019.06.021.
In many settings, tumor-associated inflammation, supported mainly by innate immune cells, contributes to tumor growth. Initial innate activation triggers secretion of inflammatory, regenerative, and anti-inflammatory cytokines, which in turn shape the adaptive immune response to the tumor. Here, we review the current understanding of the intricate dialog between cancer-associated inflammation and anti-tumor immunity. We discuss the changing nature of these interactions during tumor progression and the impact of the tissue environment on the anti-tumor immune response. In this context, we outline important gaps in current understanding by considering basic research and findings in the clinic. The future of cancer immunotherapy and its utility depend on improved understanding of these interactions and the ability to manipulate them in a predictable and beneficial manner.
在许多情况下，主要由先天免疫细胞支持的肿瘤相关炎症促进了肿瘤的生长。最初的先天激活触发了炎症、再生和抗炎细胞因子的分泌，进而塑造了对肿瘤的适应性免疫反应。在这里，我们回顾了当前对癌症相关炎症与抗肿瘤免疫之间错综复杂的对话的理解。我们讨论了这些相互作用在肿瘤进展过程中变化的性质以及组织环境对抗肿瘤免疫反应的影响。在这种情况下，我们通过考虑基础研究和临床发现来概述当前理解中的重要差距。癌症免疫疗法的未来及其效用取决于对这些相互作用的更好理解，以及以可预测和有益的方式对其进行操纵的能力。
